COMPANY NEWS

August 11, 2021

Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results

Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
July 20, 2021

CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer’s, Huntington’s, and Parkinson’s Diseases

Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases
June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
March 15, 2021

CureLab Oncology adds Hong Kong to expanding scope of patent protection

Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021

CureLab Oncology Launches Veterinary Oncology Sister company, CureLab Veterinary

Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.